1. PLUVICTOTM (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use [package insert]. Novartis website. https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto_0.pdf. Approved 2022. Accessed August 1, 2022.
2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
3. Updates to appropriate use criteria for PSMA PET;Hope;J Nucl Med.,2022
4. NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines®) for prostate cancer, version 4.2002, May 10, 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf